“I am delighted to welcome Janice Lu to the Ambrx team and look forward to leveraging her knowledge of breast oncology to continue advancing ARX788 in the clinic,” said Feng Tian, Ph. D., Chairman of the Board, President and CEO. of Ambrx. “Janice has been a valuable asset as Principal Investigator for multiple Ambrx trials, including the ACE-Pan Tumor-01 Phase 1 and ACE-Breast-03 Phase 2 clinical trials, and is the perfect candidate to take on the role. from CMO to our company. I look forward to building on Janice’s expertise to continue our current research and development efforts in the treatment of oncology.”
“I am impressed with the encouraging data from ongoing clinical trials of ARX788 and Ambrx’s biological precision technology platform,” said Dr. Lu. position, assisting in the ongoing development of their clinical development pipeline and overseeing clinical operations. I believe that our joint efforts will potentially provide less toxic and highly targeted therapeutic treatment options for patients with breast, gastric and other solid tumors.
Dr. Lu has dedicated her career to managing the treatment of women with breast cancer. Prior to her role at Ambrx, Dr. Lu was Clinical Professor of Medicine and Medical Director of the Breast Oncology Program at the Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center. Prior to her role at USC, Dr. Lu was an associate professor of clinical medicine in the division of hematology and oncology at the University of California, Los Angeles. Dr. Lu, a board-certified medical oncologist, began her career at SUNY Stony Brook where she served as Director of Medical Breast Oncology for several years.
Dr. Lu received an MD from Peking University Medical School as well as a Ph.D. from Syracuse University focusing on epigenetics under the mentorship of Dr. David Allis (Rockefeller University). Dr. Lu completed his Fellowship in Hematology and Oncology at New York University School of Medicine.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical-stage biopharmaceutical company that uses an extensive genetic code technology platform to discover and develop engineered precision biologics. These include next-generation antibody-drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting peptide therapeutics for metabolic and cardiovascular diseases. Ambrx is advancing a strong portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, across multiple therapeutic areas, including its lead product candidate ARX788. Additionally, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, visit www.ambrx.com.
This press release contains certain “forward-looking statements” intended to qualify for the “safe harbor” of liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project”, “may”, “will “, “could”, “should”, “seek”, “potential” and similar expressions, and include, without limitation, express or implied statements regarding Ambrx’s beliefs and expectations regarding the progress and potential benefits of its product candidates, clinical development and strategic plans. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties associated with: the continued impact of the COVID-19 pandemic and other health risks and events public about Ambrx’s business, operations, strategy and objectives and planned milestones; Ambrx’s ability to execute its strategy, including with respect to the timing of its R&D efforts, the initiation of clinical trials and other planned milestones; risks associated with the development of new therapies, including potential delays in clinical trials and regulatory submissions and that future clinical trial results may not be consistent with preliminary results or results from preclinical or clinical studies. prior clinical trials; Ambrx’s ability to fund the operations as expected; and additional risks and uncertainties discussed in greater detail under the heading “Risk Factors” in Ambrx’s Annual Report on Form 20-F filed with the United States Securities and Exchange Commission (SEC) on April 26, 2022, and elsewhere in Ambrx’s filings and filings with the SEC. The forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. , except as may be required under applicable law.